コンテンツへスキップ
Merck

860539P

Avanti

C16 Glucosyl(β) Ceramide (d18:1/16:0)

Avanti Research - A Croda Brand

別名:

D-glucosyl-β-1,1′-N-palmitoyl-D-erythro-sphingosine

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C40H77NO8
CAS番号:
分子量:
700.04
MDL番号:
UNSPSCコード:
12352211
NACRES:
NA.25

フォーム

powder

包装

pkg of 1 × 25 mg (860539P-25mg)
pkg of 1 × 5 mg (860539P-5mg)

メーカー/製品名

Avanti Research - A Croda Brand

脂質タイプ

sphingolipids

輸送温度

dry ice

保管温度

−20°C

SMILES記法

[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

InChI Key

VJLLLMIZEJJZTE-NNTBDIJYSA-N

詳細

Glucosyl(β) Ceramide (β-GlcCer) is a naturally occurring glycolipid and an ubiquitous intracellular metabolite. It might be present in the endoplasmic reticulum or Golgi apparatus.

アプリケーション

C16 Glucosyl(β) Ceramide (d18:1/16:0) or D-glucosyl-β-1,1′-N-palmitoyl-D-erythro-sphingosine has been used as a stock solution for the in vitro treatment of bacteria and to study the role of sphingolipids on pulmonary Pseudomonas aeruginosa infections in cystic fibrosis (CF). It may be used in the quantification of lipid in green fluorescence protein (GFP) and fatty acid transport protein 4 (FATP4) cells using electrospray ionization tandem mass spectrometry (ESI-MS/MS).

生物化学的/生理学的作用

Glucosyl(β) Ceramide (β-GlcCer) is an endogenous macrophage inducible C-type lectin (Mincle) ligand, which has immunostimulatory property. It also stimulates inflammatory and acquired immune responses on myeloid cells through Mincle. It is a potential biomarker in Gaucher′s disease. β-GlcCer regulates the function of natural killer T (NKT) lymphocytes and exhibits antimetastatic effects. A balanced level of intracellular β-GlcCer is essential for maintaining tissue homeostasis.

包装

5 mL Amber Glass Screw Cap Vial (860539P-25mg)
5 mL Amber Glass Screw Cap Vial (860539P-5mg)

法的情報

Avanti Research is a trademark of Avanti Polar Lipids, LLC

保管分類コード

11 - Combustible Solids


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

860539P-5MG:
860539P-BULK:
860539P-25MG:
860539P-VAR:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Slide 1 of 2

1 of 2

Marko Jović et al.
Molecular biology of the cell, 23(8), 1533-1545 (2012-02-18)
Gaucher disease is a lysosomal storage disorder caused by a defect in the degradation of glucosylceramide catalyzed by the lysosomal enzyme β-glucocerebrosidase (GBA). GBA reaches lysosomes via association with its receptor, lysosomal integral membrane protein type 2 (LIMP-2). We found
Masashi Inafuku et al.
Lipids, 47(6), 581-591 (2012-03-20)
Natural killer (NK) T cells are well known to play important roles in both tumor rejection and the defense against infectious. Therefore, the antitumor potential of NKT cell-activating antigens have been the focus for the development of NKT cell-based immunotherapies.
E Zigmond et al.
Gut, 56(1), 82-89 (2006-12-19)
beta-Glucosylceramide, a naturally occurring glycolipid, exerts modulatory effects on natural killer T (NKT) lymphocytes. To determine whether beta-glucosylceramide can alter NKT function in opposite directions, colitis was induced by intracolonic installation of trinitrobenzenesulphonic acid, and hepatocellular carcinoma (HCC) was induced
Johanna von Gerichten et al.
Journal of lipid research, 58(6), 1247-1258 (2017-04-05)
Mammals synthesize, cell-type specifically, the diastereomeric hexosylceramides, β-galactosylceramide (GalCer) and β-glucosylceramide (GlcCer), which are involved in several diseases, such as sphingolipidosis, diabetes, chronic kidney diseases, or cancer. In contrast, Bacteroides fragilis, a member of the human gut microbiome, and the
Anik Forest et al.
Journal of proteome research, 17(11), 3657-3670 (2018-09-27)
The goal of this work was to develop a label-free, comprehensive, and reproducible high-resolution liquid chromatography-mass spectrometry (LC-MS)-based untargeted lipidomic workflow using a single instrument, which could be applied to biomarker discovery in both basic and clinical studies. For this

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)